Multiple sclerosis therapy - WyethAlternative Names: MMS-255
Latest Information Update: 19 Oct 2009
At a glance
- Originator Wyeth
- Developer Pfizer
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 16 Oct 2008 Phase-0 for Multiple sclerosis in USA (PO)